Top Page
Cogstate Ltd
(OTC:CGS)
Cogstate Ltd (CGS) vs. iShares MSCI Australia ETF (EWA)
Cogstate Ltd Business Overview & Revenue Model
Cogstate Ltd Earnings Call Summary
Cogstate Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.63M | 50.81M | 66.27M | 60.14M | 62.03M | 43.82M |
| Gross Profit | 42.32M | 30.69M | 37.60M | 12.29M | 21.63M | 10.40M |
| EBITDA | 26.58M | 16.93M | 9.90M | 8.46M | 18.07M | 8.21M |
| Net Income | 16.15M | 10.14M | 5.45M | 5.30M | 10.37M | 7.02M |
Balance Sheet | ||||||
| Total Assets | 64.77M | 64.77M | 57.84M | 81.22M | 84.99M | 68.44M |
| Cash, Cash Equivalents and Short-Term Investments | 35.56M | 35.56M | 45.11M | 43.08M | 44.50M | 31.49M |
| Total Debt | 469.92K | 469.92K | 672.72K | 569.21K | 2.05M | 2.32M |
| Total Liabilities | 16.88M | 16.88M | 25.33M | 24.60M | 37.12M | 39.43M |
| Stockholders Equity | 47.90M | 47.90M | 40.92M | 56.62M | 47.88M | 29.02M |
Cash Flow | ||||||
| Free Cash Flow | 18.91M | 8.40M | 7.12M | -1.53M | 8.54M | 17.24M |
| Operating Cash Flow | 19.40M | 11.48M | 10.00M | 1.76M | 13.45M | 21.61M |
| Investing Cash Flow | -4.85M | -2.24M | -1.68M | -3.29M | -4.91M | -3.52M |
| Financing Cash Flow | -5.98M | -3.79M | -4.91M | -1.33M | 1.05M | -246.11K |
Cogstate Ltd Technical Analysis
Cogstate Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$471.97M | 30.05 | 22.84% | 0.74% | 21.47% | 89.09% | |
59 Neutral | AU$126.24M | 78.33 | 1.89% | ― | 10.06% | ― | |
57 Neutral | AU$15.10M | -3.26 | -27.84% | ― | 6.77% | -8.45% | |
55 Neutral | AU$89.77M | -9.77 | -8647.54% | ― | 25.98% | 21.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | AU$16.45M | -0.24 | -240.60% | ― | -48.41% | -7200.00% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― |
Cogstate Ltd Corporate Events
Cogstate Limited has announced a change in the director’s interest, specifically for Bradley O’Connor, reflecting a shift in securities holdings. The change involved the sale of 338,429 ordinary shares and the exercise of 399,500 employee options, resulting in a new holding of 5,400,000 ordinary shares and 500,000 employee options. This adjustment in securities is part of the company’s ongoing management of its executive interests and could impact its market positioning and stakeholder perceptions.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced the quotation of 399,500 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from October 17, 2025. This move reflects the company’s ongoing efforts to enhance its capital structure and potentially strengthen its market position, offering stakeholders an opportunity to engage with the company’s growth trajectory.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd announced that its CEO, Brad O’Connor, sold 338,429 shares to fund the exercise of 399,500 employee share options and to manage related debts and tax obligations. Following these transactions, Mr. O’Connor’s shareholding increased to 6,400,000 ordinary shares. This strategic move reflects the CEO’s commitment to maintaining a significant stake in the company while managing financial obligations, potentially impacting stakeholder confidence and market perception.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd announced that all resolutions were passed at its 2025 Annual General Meeting, including the re-election of directors and the renewal of the Employee Equity Plan. This outcome reflects strong shareholder support and may positively impact the company’s strategic initiatives and governance, reinforcing its position in the neuroscience technology industry.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd reported a record-breaking fiscal year 2025, with revenue reaching $53.1 million, a 22% increase, and a net profit before tax of $13.9 million, reflecting nearly 100% growth. The company’s core business in clinical trials generated $50.6 million in revenue, marking a 28% increase, and new contract sales surged by 53% to $41.3 million. The company’s operational rigor and market leadership contributed to a significant expansion in earnings leverage, with EBITDA and EBIT margins rising to 30% and 25%, respectively. These results underscore Cogstate’s strategic progress and growing momentum, positioning the company strongly for the future.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has reported a significant increase in demand for its services, driven by growth in the R&D market for central nervous system diseases and an expansion of its customer base. The company achieved its second-highest quarterly sales contracts in history, with a notable diversification in the indications for these contracts. Despite the increase in operational costs due to growth initiatives, Cogstate expects revenue for the first half of 2026 to improve by 18-20% compared to the previous year. The company is investing in additional resources and technology to support its expansion, although this may slightly impact margins.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd, a company listed on the Australian Securities Exchange (ASX) under the code CGS, has announced the quotation of additional securities. The company has issued a total of 1,147,957 ordinary fully paid shares across several dates in August and September 2025. This move is part of their strategy to enhance liquidity and potentially attract more investors, which could impact their market positioning positively.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Limited announced a change in the director’s interest, specifically involving Martyn Myer. The notice reveals that 2,500,000 ordinary shares were transferred from Myer and Myer Pty Ltd ATF Whereabouts Superannuation Fund to Trilane Industries Limited, both indirectly associated with Martyn Myer. This change reflects a reallocation of shares within entities linked to the director, potentially impacting the company’s shareholder structure and signaling strategic financial adjustments.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Limited announced a change in the director’s interest as Richard Mohs acquired 13,000 ordinary shares through the OTC market, increasing his total holdings to 80,000 shares. This acquisition reflects a strategic move by the director, potentially signaling confidence in the company’s future prospects and stability, which could positively impact stakeholder perception and market positioning.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Limited has announced a change in the interest of its director, Bradley O’Connor, as per the latest notice. The update reveals that 500,000 employee options have lapsed due to unmet performance conditions, impacting the director’s holdings. This change reflects the company’s ongoing adjustments in its executive compensation and performance evaluation strategies, which may influence stakeholder perceptions and market positioning.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd’s recent earnings call painted a picture of robust financial health and strategic growth, despite facing some challenges. The sentiment was largely positive, with the company reporting significant revenue and profit growth. Cogstate is actively expanding its market reach and capabilities through strategic partnerships and product innovations, notably with Medidata and the development of AI-powered products. However, the company acknowledged challenges such as a decline in healthcare revenue and potential margin pressure due to increased investments.
Cogstate Limited has announced a change in the director’s interest, with Bradley O’Connor acquiring an additional 50,327 ordinary shares on the market at $1.738 per share, valued at $87,485. This acquisition reflects a strategic move that may impact the company’s market perception and stakeholder confidence, as it indicates potential growth or confidence in the company’s future performance.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.19 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd, an Australian company listed on the ASX, specializes in digital brain health assessments and quality assurance services for clinical trials, primarily focusing on central nervous system diseases. In its latest earnings report, Cogstate announced record revenue and profit for FY25, with total revenue reaching US$53.1 million, a 22% increase from the previous year. The company also reported a significant rise in net profit before tax to US$13.9 million, marking a 96% increase, and declared its maiden annual dividend, reflecting strong financial performance and operational efficiency. Key highlights include a 28% increase in clinical trials revenue and strategic partnerships that are expected to drive future growth. Looking ahead, Cogstate plans to expand its reach through partnerships and technological advancements, positioning itself for sustained growth in the CNS research and development sector.
Cogstate Ltd has released its FY25 financial results, highlighting the company’s business and financial outlook. The company invites investors to a live webcast and Q&A session to discuss these results. The announcement underscores Cogstate’s ongoing commitment to supporting research and clinical care needs globally, with a focus on innovative cognitive assessment technologies. This release is significant for stakeholders as it reflects Cogstate’s strategic positioning in the neuroscience technology industry, potentially impacting future business operations and market engagements.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Limited announced record financial and operational performance for FY25, with significant growth driven by its Clinical Trials business. The company reported a 22% increase in group revenue to $53.1 million and a 96% rise in net profit before tax to $13.9 million. The growth was fueled by a 53% increase in new sales contracts for clinical trials, despite a decline in healthcare revenue due to changes in licensing agreements. Cogstate’s strategic partnership with Medidata and its focus on launching AI-powered products in FY26 are expected to strengthen its position in the CNS clinical research market.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced a dividend distribution of AUD 0.02000000 per share for its ordinary fully paid securities, with the ex-date set for August 27, 2025, and the payment date on September 29, 2025. This announcement reflects the company’s financial performance for the period ending June 30, 2025, and may impact stakeholders by providing a return on investment, indicating stable financial health and potential future growth.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced record revenue and profit, declaring its first annual dividend, highlighting its strong financial performance. The company continues to make strides in the healthcare sector, particularly in Alzheimer’s research, by supporting decentralized trials and receiving funds from the Alzheimer’s Drug Discovery Foundation, which underscores its significant role in advancing therapeutic developments.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd reported a substantial increase in revenue and profit for the financial year ending June 30, 2025. The company achieved a 22.3% rise in total revenue, driven largely by a 28.2% increase in clinical trials revenue, while healthcare revenue saw a decline. Profit before income tax nearly doubled, and the company declared its first dividend, indicating strong financial performance and potential positive implications for stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has released its FY25 Appendix 4G and Corporate Governance Statement, demonstrating its adherence to ASX corporate governance principles. This announcement underscores Cogstate’s commitment to transparency and regulatory compliance, which may enhance its reputation and trust among stakeholders, potentially impacting its market position positively.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd announced it will release its full year results for the financial year ending June 30, 2025, on August 22, 2025. The announcement includes an invitation for investors to join a live webcast and Q&A session with key executives. This release is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced the issuance of 300,000 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure, potentially impacting its market positioning and providing new opportunities for stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced its upcoming Annual General Meeting scheduled for October 16, 2025, with director nominations required 45 business days prior. This meeting is a significant event for the company, potentially impacting its governance and strategic direction, and it reflects the company’s ongoing commitment to its stakeholders and market presence.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.